Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPULSAR-CRC
NCT06841159Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in colorectal cancer (metastatic) (mCRC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06841159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841159.